rosuvastatin + atorvastatin + ezetimibe

This entry describes a therapeutic approach involving the co-administration of rosuvastatin, atorvastatin, and optionally ezetimibe, rather than a single fixed-dose combination product. Rosuvastatin and atorvastatin are both HMG-CoA reductase inhibitors (statins) that reduce cholesterol synthesis in the liver, leading to increased expression of LDL receptors and enhanced clearance of LDL cholesterol from the bloodstream. Ezetimibe is a cholesterol absorption inhibitor that acts in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) protein, thereby reducing the absorption of dietary and biliary cholesterol. While fixed-dose combinations of a single statin with ezetimibe (e.g., rosuvastatin/ezetimibe or atorvastatin/ezetimibe) are available and widely used for managing hyperlipidemia, a fixed-dose combination containing both rosuvastatin and atorvastatin, with or without ezetimibe, is not a commonly available product due to overlapping mechanisms of action and potential for increased adverse effects when combining two statins. These drugs are primarily indicated for the treatment of hyperlipidemia and the prevention of cardiovascular disease.

Brand names

CrestorLipitorZetiaRoszetRidutrinRosuzetLiptruzetAtozetStorvas EZLipi EZAztor EZAtorva EAtorec EZTonact EZAvas-EZTG-Tor EZAtorsave EZZivast E